Showing 3001-3010 of 4166 results for "".
- Alcon Introduces AcrySof IQ PanOptix Trifocal IOL in the US, the First and Only FDA-Approved Trifocal Lenshttps://modernod.com/news/alcon-introduces-acrysof-iq-panoptix-trifocal-iol-in-the-us-the-first-and-only-fda-approved-trifocal-lens/2476827/Alcon announced the FDA approval and the initial commercial launch of the AcrySof IQ PanOptix Trifocal IOL, the first and only trifocal lens approved in the United States. PanOptix is clinically shown to deliver an exceptional combination of near, intermediate, and distance vision while reducing
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- Data from BioTime’s OpRegen and Retinal Restoration Programs to Be Presented at ARVO 2018https://modernod.com/news/data-from-biotimes-opregen-and-retinal-restoration-programs-to-be-presented-at-arvo-2018/2480231/BioTime announced that data from the ongoing OpRegen clinical trial and Retinal Restoration program will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) meeting taking place from April 29 – May 3, 2018, in Honolulu, Hawaii. The scheduled times (note
- Zeiss Introduces Video Laryngoscopehttps://modernod.com/news/zeiss-introduces-video-laryngoscope/2478531/With the outbreak of the COVID-19 crisis earlier this year, the Medical Technology segment of Zeiss focused on he
- Atsena Therapeutics Initiates Part B of Phase 1/2 Clinical Trial Evaluating Gene Therapy ATSN-201 to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-initiates-part-b-of-phase-12-clinical-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482602/Atsena Therapeutics announced the initiation of Part B of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a gene therapy product candidate, leverages AAV.SPR, the company’s n
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase 1/2 Trial Evaluating Gene Therapy for XLRShttps://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/Atsena Therapeutics announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 utilizes AAV.SPR, the company’s novel sprea
- Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for its First Pivotal Clinical Trial of OTX-TKI in Wet AMDhttps://modernod.com/news/ocular-therapeutix-receives-fda-agreement-under-special-protocol-assessment-spa-for-its-first-pivotal-clinical-trial-of-otx-tki-in-wet-amd/2481928/Ocular Therapeutix announced it has received written agreement regarding the overall design from the FDA under a Special Protocol Assessment (SPA) for the company’s ongoing pivotal phase 3 clinical trial for Axpaxli (axitinib intravitreal implant), for the treatment of wet ag
- Atsena Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of ATSN-201 for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-announces-first-patient-dosed-in-phase-12-clinical-trial-of-atsn-201-for-the-treatment-of-x-linked-retinoschisis/2481796/Atsena Therapeutics announced the first patient has been dosed in the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 uses AAV.SPR, the company’s novel spreading c
- Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of RP Associated with Usher Syndromehttps://modernod.com/news/nacuity-pharmaceuticals-achieves-target-enrollment-for-phase-12-clinical-trial-of-npi-001-for-the-treatment-of-rp-associated-with-usher-syndrome/2481641/Nacuity Pharmaceuticals announced that target enrollment of 48 patients has been reached in the SLO-RP phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). “We are pleased to reach our target enrollment,